PADCEV and KEYTRUDA Boost Survival in Bladder Cancer Care
August 12, 2025
Pfizer Inc and Astellas Pharma Inc have announced encouraging early results from the Phase 3 EV-303 (KEYNOTE-905) trial. The study evaluated PADCEV (enfortumab vedotin), an